Role of RASSF1-A gene in early detection of colorectal carcinogenesis

Thaer Ali Hussein; Ahmad Shandookh Hameed; Mohamed Hussein Amer

doi:10.53730/ijhs.v6nS9.12831

Authors

Thaer Ali Hussein
thaerali@stu.edu.iq
University of Southern Technical, Institute of Al-Nasiriya Technical, Department of Nursing, Iraq
Ahmad Shandookh Hameed University of Southern Technical, Institute of Al-Nasiriya Technical, Department of Nursing, Iraq
Mohamed Hussein Amer University of Southern Technical, Institute of Al-Nasiriya Technical, Department of Nursing, Iraq

Keywords:

RASSF1-A, tumour suppressor gene, Ras-association domain, methylation, colorectal cancer

Abstract

Background: Colorectal cancer (CRC) is a malignant neoplasm originating from the un-controlled cell proliferations in epithelial cells lining of rectum, colon, or appendix. RASSFs wereconcerned in tumourigenesis and numerous members of family are presently supposed to be tumour suppressor, Aim and objectives: Estimate- function of RASSF1-A methylated gene in theCRC pathogenesis, detect RASSF1-A methylated gene cutoff value for diagnosis and using RASSF1-A gene as abio-marker to detect recurrence after surgery, Subjects and methods: This is a prospective observational case-control researchperformed on 50 cases diagnosed as CRC by endoscopy and histopathology and 50 control persons at Aswan university hospital and internal medicine department., Results: there is high significant relation between RASSF 1A and development of colorectal-cancer, Conclusion: Genetical mutations in the Kras genes and epigenetic modifications in RASSF1-A, FHIT and MGMT genes in sporadic CRC are accompanying with the generalprogress of the disorder and can be utilized as diagnostical or prognostically biomarkers in this collection of tumours.

Downloads

Download data is not yet available.

References

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A. (2015). Global Cancer Statistics, 2012. CA a cancer J Clin;65(2):87–108. Available from: http://onlinelibrary.wiley.com/doi/10.3322/caac.21262/abstract

Bardhan K, Liu K. (2013). Epigenetics and colorectal cancer pathogenesis. Cancers (Basel); 5(2):676-713.

Richter AM, Pfeifer GP, Dammann RH. (2009).The RASSF proteins in cancer: from epigenetic silencing to functional characterization. BiochimBiophys Acta;1796:114–28.

Fernandes MS, Carneiro F, Oliveira C, Seruca R (2013). Colorectal cancer and RASSF family—a special emphasis on RASSF1-A. Int J Cancer; 132:251–258.

Balgkouranidou I, Matthaios D, Karayiannakis A, Bolanaki H, Michailidis P, Xenidis N. (2015). Prognostic role of APC and RASSF1-A promoter methylations status in cell free circulating DNA of operable gastric cancer patients. Mutat Res; 778:46-51.

Balgkouranidou, I. (2019). The Methylations Status of RASSF1-A and APC Represents a Valuable Prognostic Indicator in Gastrointestinal Malignancies. EC Gastroenterology and Digestive System; 6, 582-597.‏

Sinha R, Hussain S, Mehrotra R, Kumar RS, Kumar K, Pande P, et al. (2013).Kras gene mutation and RASSF1-A, FHIT and MGMT gene promoter hyper-methylation: indicators of tumour staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population. PLoS ONE 8:e60142.

Matthaios, D., Balgkouranidou, I., Karayiannakis, A., Bolanaki, H., Xenidis, N., Amarantidis, K., et al. (2016). Methylations status of the APC and RASSF1-A promoter in cell free circulating DNA and its prognostic role in patients with colorectal cancer. Oncology letters; 12(1), 748-756.‏

Lee S, Hwang KS, Lee HJ, Kim JS, Kang GH. (2004). Aberrant CpG island hyper-methylations of multiple genes in colorectal neoplasia. Lab Invest; 84(7):884-93.

Sakamoto N, Terai T, Ajioka Y, Abe S, Kobayasi O, Hirai S, et al. (2004). Frequent hyper-methylations of RASSF1-A in early flat-type colorectal tumours. Oncogene; 23(55):8900-7.

GhazalehHA, Chow RS, Choo SL, Pham D, Olesen JD, Wong RX, et al. (2010). 14-3-3 mediated regulation of the tumour suppressor protein, RASSF1-A. Apoptosis; 15(2):117-27.

Wagner KJ, Cooper WN, Grundy RG, Caldwell G, Jones C, Wadey RB, et al. (2002). Frequent RASSF1-Atumour suppressor gene promoter methylations in Wilms' tumour and colorectal cancer. Oncogene; 21(47):7277-82.

van Engeland M, Roemen GM, Brink M, Pachen MM, Weijenberg MP, de Bruïne AP, et al.(2002). K-ras mutations and RASSF1-A promoter methylations in colorectal cancer. Oncogene; 21(23):3792-5.

Gonzalo V, Lozano JJ, Muñoz J, Balaguer F, Pellisé M, Rodríguez de Miguel C, et al.,2010. Aberrant gene promoter methylations associated with sporadic multiple colorectal cancer. PLoS One; 5(1):e8777.

Ahlquist T, Bottillo I, Danielsen SA, Meling GI, Rognum TO, Lind GE, et al. (2008). RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1-A. Neoplasia; 10(7):680-6, 2 p following 686.

An B. (2010). “Characteristic methylations profile in CpG island methylator phenotype-negative distal colorectal cancers”. International Journal of Cancer; 127(9): 2095-2105.

Wang HL. (2014). “Promoter methylations of the RASSF1-A gene may contribute to colorectal cancer susceptibility: a meta-analysis of cohort studies”. Annals of Human Genetics 78.3 208-216.

Nilsson TK. (2013). “DNA methylations of the p14ARF, RASSF1-A and APC1A genes as an independent prognostic factor in colorectal cancer patients”. International Journal of Oncology; 42(1): 127-133.

Cejas P, López-Gómez M, Aguayo C, Madero R, de Castro Carpeño J, Belda-Iniesta C, et al. (2009). KRAS mutations in primary colorectal cancer tumours and related metastases: a potential role in prediction of lung metastasis. PLoS One; 4(12):e8199.

Mannan A, Hahn-Strömberg V. (2012). K-ras mutations are correlated to lymph node metastasis and tumour stage, but not to the growth pattern of colon carcinoma. APMIS; 120(6):459-68.